660 results found

Lucy Johnson, COO of HGF, discusses the evolving IP landscape, highlighting AI's role in enhancing strategies, combating bad actors, adapting to global regulations, and fostering cross-departmental collaboration for innovation.

HGF has been asked to include intellectual property (IP) valuation as a topic at its IP in Healthcare Conference on a few occasions now.

Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response.

Advanced materials science is revolutionizing space exploration, from lightweight composites reducing launch costs to radiation-shielding alloys protecting deep space missions. As governments and private companies pursue sustainable exploration and settlement beyond Earth, innovations in materials engineering are becoming both a competitive advantage and a commercial imperative, with intellectual property protection playing an increasingly critical role in securing investment and building long-term value.

G 1/19's requirement that the technical effect be present throughout the scope of the claim is understood as meaning that when a patent application is drafted...

The status of our offices can be found here and is updated on a daily basis. Please do not send any documents by post at this time as our UK offices continue...

On 1 June 2023, ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE lodged a statement of revocation of the European Patent No. EP 3056564 B1 entitled "method for purification of retinal pigment epithelial cells"...

As the British summer swings once again between sunburn and showers, it's a great time to take stock of what the first half of the year has delivered by way of IP decisions.

A new referral to the Court of Justice of the EU will once again consider what is meant by the “first marketing authorisation” requirement of Article 3(d) of the EU medicines SPC Regulation. Specifically, the CJEU has been asked to clarify whether a veterinary marketing authorisation (MA) for a medicine can be considered the “first” MA for SPC purposes when there has been a prior MA for the same product as a human medicine.

National Dutch and European patents are governed by the Dutch Patent Act 1995. The act and the courts have sought to harmonise Dutch patent practice with the European Patent Convention (EPC).

In G1/24, the Enlarged Board of Appeal (EBA) codified how claims should be interpreted for assessing patentability: in consultation with the description.

As artificial intelligence becomes embedded in product design, data infrastructure, and everyday workflows, organisations face a critical shift from theoretical AI governance frameworks to continuous operational decision-making.

The earliest identified date of a patient presenting with symptoms of a "novel coronavirus" in Wuhan, China is reported to be 1 December 2019.

Missing a patent renewal fee can be distressing, but it doesn't always mean your patent rights are lost forever. This comprehensive guide examines the restoration procedures across the UK, Europe, and key European jurisdictions, explaining the different legal standards—from the UK's 'unintentional' test to the stricter 'all due care' requirement at the EPO—and the critical timelines you must meet to successfully restore lapsed patent rights.

The Unified Patent Court's long-arm jurisdiction has emerged as a critical concern for manufacturers operating outside Europe, particularly those based in the US and China. Recent decisions demonstrate how corporate structure, European subsidiaries, and regulatory intermediaries can expose companies to pan-European patent litigation extending beyond UPC member states. Understanding these jurisdictional mechanisms and their implications for operations in non-UPC countries like the UK, Spain, and Switzerland

A Unitary Patent will be a patent offering uniform protection in up to 25 participating Member States of the European Union.

Geopolitical conflicts and climate change are threatening global food security by disrupting fertiliser supply chains and driving up costs. European companies are developing innovative solutions ranging from green ammonia production and nitrogen fixation technologies to circular fertilisers derived from waste streams and biological alternatives that enhance nutrient efficiency.

The EPO has announced (here and here) that for the second year in a row, new EPO Official Fees will apply from 1 April 2023. The new amounts will apply to payments...